Issue 24-3, 2025

Review

https://doi.org/10.38025/2078-1962-2025-24-3-123-139

Optimising the Timing of Health Resort Treatment in Patients with Arterial Hypertension and Increased Meteosensitivity: a Prospective Study

View article (Download PDF file)



Download XML file

ORCIDBair A. Zhigzhitov1,*, ORCIDLarisa A. Marchenkova1, ORCIDVladimir B. Knyazkov2, ORCIDDaria D. Lebedeva3, ORCIDLev G. Agasarov1,4

1 National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia
2 Russian University of Medicine, Moscow, Russia
3 Central Clinical Hospital of the Administrative directorate of the President of the Russian Federation, Moscow, Russia
4 I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia


ABSTRACT

INTRODUCTION.  The clinically frequently detected combination of ronchopathy (snoring) and obstructive sleep apnea is an important problem in modern medicine. Correction of this pathology is performed surgically with known success, however, in this regard, it is necessary to point out the features of the condition of most patients that prevent surgical intervention, as well as the observed frequency of recurrence of the process. In addition, the importance of transient factors in upper respiratory tract obstruction, which require correction during the acute phase, indicates the prospects for the development of modern therapeutic approaches.

AIM.  To study the effectiveness of the original spectral phototherapy method in the complex treatment of patients with ronchopathy and obstructive sleep apnea syndrome.

MATERIALS AND METHODS.  The study included 90 patients (67 men and 23 women) aged 30 to 75 years with bronchopathy and moderate obstructive sleep apnea. The examination of these individuals was carried out using questionnaires, pharyngoscopy, respiratory monitoring, and biochemical analysis (calculating the balance of a number of trace elements) before, 10 days, and 3 months after treatment. These patients were divided into three groups, each consisting of 30 people. In all groups, standard treatment was performed, including positional therapy, exercises for facial muscles, etc. In group 1, they limited themselves to this, while in group 2, they additionally used intraoral mouthguards, and in group 3, mouthguards and spectral phototherapy were used.

RESULTS AND DISCUSSION.  The data from the questionnaire survey performed after treatment reflected the regression of disease manifestations in patients of all groups, however, with the priority of the third group, the treatment of which included spectral phototherapy. A decrease in the intensity of snoring and a decrease in the number of episodes of sleep apnea with improved sleep quality was noted after 10 days of treatment in 12 patients of the first group, 18 in the second and 21 in the third, and after 3 months of treatment, the preservation of the therapeutic effect was noted in 9 patients of the first group, 11 in the second and 15 in the third, which correlated with an increase in potassium, magnesium, manganese, and calcium, and corresponded to the transition of OSA from moderate to mild.

CONCLUSION.  Spectral phototherapy is an effective method indicated for use in the complex treatment of patients with ronchopathy and obstructive sleep apnea syndrome of moderate severity.


KEYWORDS: neurodevelopmental therapy, Bobath-therapy, children, perinatal nervous system injury, cerebral palsy, neurorehabilitation

FOR CITATION:

Khan M.A., Kostenko E.V., Mikitchenko N.A., Degtyareva M.G., Shungarova Z.H. Outlook for the Use of Neurodevelopmental Therapy in Children with Perinatal Central Nervous System Damage: a Review. Bulletin of Rehabilitation Medicine. 2025; 24(3):102–112. https://doi.org/10.38025/2078-1962-2025-24-3-102-112 (In Russ.). 

FOR CORRESPONDENCE:

Natalya A. Mikitchenko, Е-mail: mikitchenko_nata@mail.ru, 6057016@mail.ru


References:

  1. Xing Y., Bai Y. A Review of Exercise-Induced Neuroplasticity in Ischemic Stroke: Pathology and Mechanisms. Mol Neurobiol. 2020; 57(11): 4218–4231. https://doi.org/10.1007/s12035-020-02021-1

  2. Skaper S. Neurotrophic Factors: An Overview. In: Skaper S., editor. Neurotrophic Factors: Methods and Protocols. New York, NY: Springer. 2018. p. 1–17. https://doi.org/10.1007/978-1-4939-7571-6_1

  3. Brunelli S., Giannella E., Bizzaglia M., et al. Secondary neurodegeneration following Stroke: what can blood biomarkers tell us? Front Neurol. 2023; 14: 1038808. https://doi.org/10.3389/fneur.2023.1198216

  4. He J., Chen L., Tang F., et al. Multidisciplinary team collaboration impact on NGF, BDNF, serum IGF-1, and life quality in patients with hemiplegia after stroke. Cell Mol Biol (Noisy-le-grand). 2023; 69(12): 57–64. https://doi.org/10.14715/cmb/2023.69.12.10

  5. Hernández-del Caño C., Varela-Andrés N., Cebrián-León A., Deogracias R. Neurotrophins and Their Receptors: BDNF’s Role in GABAergic Neurodevelopment and Disease. Int J Mol Sci. 2024; 25(15): 8312. https://doi.org/10.3390/ijms25158312

  6. Liu W., Wang X., O’Connor M., et al. Brain-derived neurotrophic factor and its potential therapeutic role in Stroke comorbidities. Neural Plast. 2020; 2020: 8107274. https://doi.org/10.1155/2020/1969482

  7. Sims-Knight C., Wilken-Resman B., Smith C., et al. Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research. Neural Plast. 2022; 2022: 9830128. https://doi.org/10.1155/2022/3889300

  8. Чуканова А.С., Гулиева М.Ш., Чуканова Е.И., Багманян С.Д. Применение сывороточных биомаркеров повреждения, апоптоза и нейротро­фичности в оценке прогноза ишемического инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2022; 122(8–2): 48–53. [Chukanova A.S., Gulieva M.Sh., Chukanova E.I., Bagmanyan S.D. A panel of serum biomarkers, including damage, apoptosis and neurotrophic markers, for the assessment of prognosis of the course of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2022; 122 (8–2): 48–53. https://doi.org/10.17116/jnevro202212208248 https://doi.org/10.17116/jnevro202212208248 (In Russ.).]

  9. Shahnawaz A., Varun Kumar S., Varshaa Ch., Rameshwar Nath Ch. Neurorehabilitation and its relationship with biomarkers in motor recovery of acute ischemic stroke patients — A systematic review. J Clin Sci Res. 2024; 13(2):125. http://dx.doi.org/10.4103/jcsr.jcsr_16_23

  10. Ashcroft S., Ironside D., Johnson L., et al. Effect of Exercise on Brain-Derived Neurotrophic Factor in Stroke Survivors: A Systematic Review and Meta- Analysis. Stroke. 2022; 53(12): 3706–3716. https://doi.org/10.1161/strokeaha.122.039919

  11. Karantali E., Kazis D., Papavasileiou V., et al. Serum BDNF Levels in Acute Stroke: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2021; 57(3): 297. https://doi.org/10.3390/medicina57030297

  12. Mojtabavi H., Shaka Z., Momtazmanesh S., et al. Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis. J Transl Med. 2022; 20(1): 233. https://doi.org/10.1186/s12967-022-03312-y

  13. Zhou B., Mu K., Yu X., Shi X. Serum Levels and Clinical Significance of NSE, BDNF and CNTF in Patients with Cancer-associated Ischemic Stroke Complicated with Post-stroke Depression. Actas Esp Psiquiatr. 2024; 52(4): 474–483. https://doi.org/10.62641/aep.v52i4.1667

  14. Liu X., Fang J.-C., Zhi X.-Y., et al. The Influence of Val66Met Polymorphism in Brain-Derived Neurotrophic Factor on Stroke Recovery Outcome: A Systematic Review and Meta-analysis. Neurorehabil Neural Repair. 2021; 35(6): 550–560. https://doi.org/10.1177/15459683211014119

  15. Santoro M., Siotto M., Germanotta M., et al. BDNF rs6265 Polymorphism and Its Methylation in Patients with Stroke Undergoing Rehabilitation. Int J Mol Sci. 2020; 21(22): 8438. https://doi.org/10.3390/ijms21228438

  16. Sukhan D., Liudkevych H., Olkhova I., et al. The role of neurotrophins in post-stroke rehabilitation. Rep Vinnytsia Nation Med Univ. 2021; 25(4): 651–656. https://doi.org/10.31393/reports-vnmedical-2021-25(4)-25

  17. Ledreux A., Håkansson K., Carlsson R., et al. Differential Effects of Physical Exercise, Cognitive Training, and Mindfulness Practice on Serum BDNF Levels in Healthy Older Adults: A Randomized Controlled Intervention Study. J Alzheimers Dis. 2019; 71(4): 1245–1261. https://doi.org/10.3233/JAD-190756

  18. Ploughman M., Eskes G., Kelly L., et al. Synergistic Benefits of Combined Aerobic and Cognitive Training on Fluid Intelligence and the Role of IGF-1 in Chronic Stroke. Neurorehabil Neural Repair. 2019; 33(3): 199–212. https://doi.org/10.1177/1545968319832605

  19. Björkholm C., Monteggia L. BDNF — a key transducer of antidepressant effects. Neuropharmacology. 2016; 102: 72–79. https://doi.org/10.1016/j.neuropharm.2015.10.034

  20. Cubillos S., Engmann O., Brancato A. BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions. Int J Mol Sci. 2022; 23(22): 14445. https://doi.org/10.3390/ijms232214445

  21. Brunello C., Cannarozzo C., Castrén E. Rethinking the role of TRKB in the action of antidepressants and psychedelics. Trends Neurosci. 2024; 47(11): 865–874. https://doi.org/10.1016/j.tins.2024.08.011

  22. Widodo J., Asadul A., Wijaya A., Lawrence G. Correlation between Nerve Growth Factor (NGF) with Brain Derived Neurotropic Factor (BDNF) in Ischemic Stroke Patient. Bali Med J. 2016; 5(2): 10. https://doi.org/10.15562/bmj.v5i2.199

  23. Li X., Li F., Ling L., et al. Intranasal administration of nerve growth factor promotes angiogenesis via activation of PI3K/Akt signaling following cerebral infarction in rats. Am J Transl Res. 2018; 10(11):3481–3492.

  24. Luan X., Qiu H., Hong X., et al. High Serum Nerve Growth Factor Concentrations Are Associated with Good Functional Outcome at 3 Months Following Acute Ischemic Stroke. Clinica Chimica Acta. 2019; 488: 20–24. https://doi.org/10.1016/j.cca.2018.10.030

  25. Gu C.-L., Ma L., Hou Y., et al. Exploring the Cellular and Molecular Basis of Nerve Growth Factor in Cerebral Ischemia Recovery. Neuroscience. 2024; 566: 190–197. https://doi.org/10.1016/j.neuroscience.2024.12.049

  26. Colitti N., Desmoulin F., Le Friec A., et al. Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de Novo Brain Tissue. Front Cell Neurosci. 2022; 16: 871532. https://doi.org/10.3389/fncel.2022.871532

  27. Moghanlou A., Yazdanian M., Roshani S., et al. Neuroprotective effects of pre-ischemic exercise are linked to expression of NT-3/NT-4 and TrkB/TrkC in rats. Brain Res Bull. 2023; 194: 54–63. https://doi.org/10.1016/j.brainresbull.2023.01.004

  28. Chung J.-Y., Kim M.-W., Im W., et al. Expression of Neurotrophin-3 and TrkC Following Focal Cerebral Ischemia in Adult Rat Brain with Treadmill Exercise. J Korean Med Sci. 2017; 32(9): 1486–1492. https://doi.org/10.1155/2017/9248542

  29. Chung J.-Y., Kim M.-W., Bang M.-S., Kim M. Increased Expression of Neurotrophin 4 Following Focal Cerebral Ischemia in Adult Rat Brain with Treadmill Exercise. PLoS One. 2013; 8(3): e52461. https://doi.org/10.1371/journal.pone.0052461

  30. Cortés D., Carballo-Molina O., Castellanos-Montiel M., Velasco I. The Non-Survival Effects of Glial Cell Line-Derived Neurotrophic Factor on Neural Cells. Front Mol Neurosci. 2017; 10: 287. https://doi.org/10.3389/fnmol.2017.00258

  31. Zhang Z., Sun G., Ding S. Glial Cell Line-Derived Neurotrophic Factor and Focal Ischemic Stroke. Neurochem Res. 2021; 46(10): 2638–2650. https://doi.org/10.1007/s11064-021-03266-5

  32. Zhang N., Zhang Z., He R., et al. GLAST-CREERT2 Mediated Deletion of GDNF Increases Brain Damage and Exacerbates Long-Term Stroke Outcomes After Focal Ischemic Stroke in Mouse Model. Glia. 2020; 68(11): 2395–2414. https://doi.org/10.1002/glia.23848

  33. Куракина А.С., Семенова Т.Н., Щелчкова Н.А. и др. Прогностическая значимость определения уровня глиального нейротрофического фактора в плазме крови у больных с ишемическим инсультом. Пермский медицинский журнал. 2021; 38(2):95–102. https://doi.org/10.17816/pmj38295-102 [Kurakina A.S., Semenova T.N., Shchelchkova N A. et al. The prognostic significance of determining the level of glial neurotrophic factor in blood plasma in patients with ischemic stroke. Perm Medical Journal. 2021; 38(2): 95–102. https://doi.org/10.17816/pmj38295-102 (In Russ.).]

  34. Pasquin S., Sharma M., Gauchat J.-F. Cytokines of the LIF/CNTF Family and Metabolism. Cytokine. 2016; 82: 122–124. https://doi.org/10.1016/j.cyto.2015.12.019

  35. Stansberry W., Pierchala B. Neurotrophic factors in the physiology of motor neurons and their role in the pathobiology and therapeutic approach to amyotrophic lateral sclerosis. Front Mol Neurosci. 2023; 16: 1238453. https://doi.org/10.3389/fnmol.2023.1238453

  36. Jia C., Brown R., Malone H., et al. Ciliary Neurotrophic Factor Is a Key Sex-Specific Regulator of Depressive-Like Behavior in Mice. Psychoneuroendocrinology. 2019; 100: 96–105. https://doi.org/10.1016/j.psyneuen.2018.09.038

  37. Hayes C., Valcarcel-Ares M., Ashpole N. Preclinical and clinical evidence of IGF-1 as a prognostic marker and acute intervention with ischemic stroke. J Cereb Blood Flow Metab. 2021; 41(10): 2475–2491. https://doi.org/10.1177/0271678x211000894

  38. Mehrpour M., Rahatlou H., Hamzehpur N., et al. Association of insulin-like growth factor-I with the severity and outcomes of acute ischemic stroke. Iran J Neurol. 2016; 15(4): 214–218.

  39. Armbrust M., Worthmann H., Dengler R., et al. Circulating Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 predict Three-months Outcome after Ischemic Stroke. Exp Clin Endocrinol Diabetes. 2017; 125(7): 485–491. https://doi.org/10.1055/s-0043-103965

  40. Aberg N., Aberg D., Jood K., et al. Altered Levels of Circulating Insulin-Like Growth Factor I (IGF-I) Following Ischemic Stroke Are Associated with Outcome — A Prospective Observational Study. BMC Neurol. 2018; 18: 106. https://doi.org/10.1186/s12883-018-1107-3

  41. Neeraj S., Limaye L., Braighi Carvalho L., Kramer S. Effects of Aerobic Exercise on Serum Biomarkers of Neuroplasticity and Brain Repair in Stroke: A Systematic Review. Arch Phys Med Rehabil. 2021; 102(8): 1633–1644. https://doi.org/10.1016/j.apmr.2021.04.010

  42. Guo D., Zhu Z., Zhong C., et al. Increased Serum Netrin-1 Is Associated with Improved Prognosis of Ischemic Stroke: An Observational Study from CATIS. Stroke. 2019; 50(4): 845–852. https://doi.org/10.1161/strokeaha.118.024631

  43. Xu T., Zuo P., Wang Y., et al. Serum Omentin-1 Is a Novel Biomarker for Predicting the Functional Outcome of Acute Ischemic Stroke Patients. Clin Biochem. 2018; 56:350–355. https://doi.org/10.1515/cclm-2017-0282

  44. Tiedt S., Duering M., Barro C., et al. Serum Neurofilament Light: A Biomarker of Neuroaxonal Injury After Ischemic Stroke. Neurology. 2018; 91(14): e1338–e1347. https://doi.org/10.1212/wnl.0000000000006282

  45. Gao L., Xie J., Zhang H., et al. Neuron-Specific Enolase in Hypertension Patients with Acute Ischemic Stroke and Its Value Forecasting Long-Term Functional Outcomes. BMC Geriatr. 2023; 23(1): 294. https://doi.org/10.1186/s12877-023-03986-z






Creative Commons License
The content is available under the Creative Commons Attribution 4.0 License.

©


This is an open article under the CC BY 4.0 license. Published by the National Medical Research Center for Rehabilitation and Balneology.